RVMDRevolution Medicines, Inc.Signing up patients
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Advanced Solid Tumors · Metastatic Solid Tumors · Non-small Cell Lung Cancer (NSCLC) · NSCLC · Colorectal Cancer (CRC) · CRC
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 370 (planned)
- Started
- Jan 30, 2026
- Main results expected
- May 2029
- Fully finished
- May 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of patients with adverse events (AEs)
Measured over: Up to approximately 4 years
Changes in vital signs
Measured over: Up to approximately 4 years
Changes in clinical laboratory test values
Measured over: Up to approximately 4 years
Dose Limiting Toxicities
Measured over: 28 days
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07397338 · record last updated 2026-11-04 · checked 2026-11-09 15:42 UTC